Mast Cell Agonism for Glioblastoma Immunotherapy
Year: 2026
Type: article
Abstract: Glioblastoma (GBM) is a devastating disease with an effective mortality rate of 100%. Despite decades of research, treatment advances remain relatively stagnant. However, immunotherapeutic strategies, particularly those targeting innate immunity, are increasingly showing some preclinical success. One innate immune cell population that has been understudied for immunotherapy but plays a significant role in GBM is the mast cell (MC). MCs are known to accumulate in GBM and their activation is associated with positive prognosis. Here we explore MCs as an immunotherapeutic target in two murine GBM models. We then develop MC-agonist scaffolds for interstitial delivery using the acetalated dextran (Ace-DEX) controlled release polymer platform. We examine the scaffolds’ effect on tumor growth and mouse survival in two GBM models. Further, we evaluated multi-organ immunophenotyping to establish the resultant immunological activity following local delivery of a MC agonist.
Source: UNC Libraries
DOI: 10.17615/hx7f-tz81
Institution: University of North Carolina at Chapel Hill
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7196932274
FWCI:
Cites:
Cited by:
Related to: